生物医药公司Eikon Therapeutics(EIKN.US)IPO定价18美元募资3.812亿 今晚登陆纳斯达克

智通财经
Feb 05

智通财经APP获悉,生物医药公司Eikon Therapeutics(EIKN.US)周三表示,其美国首次公开发行(IPO)募资3.812亿美元,共发行约2120万股普通股,发行价定为每股18美元。此次发行价位于该公司16至18美元目标区间上限。

据了解,本次上市计划进行之际,美国IPO市场在2026年已显现回暖迹象。去年10月的政府停摆曾导致多家企业推迟上市计划。而今年初,生物科技企业IPO同样迎来复苏,SpyGlass Pharma(SGP.US)、AgomAb Therapeutics(AGMB.US)等生物医药研发企业均已在1月递交美国上市申请。

Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立,公司目前正布局多款癌症实验性疗法研发管线。

公司研发进度最快的候选药物EIK1001,正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验,该研究的中期分析数据预计将于2026年下半年公布。

Eikon Therapeutics的股票将于周四在纳斯达克挂牌交易,股票代码为“EIKN”。本次IPO的承销商包括摩根大通摩根士丹利、美国银行证券、Cantor及瑞穗证券。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10